| Literature DB >> 30686832 |
Mohamed S M Nassar1, Walaa A Hazzah1, Wafaa M K Bakr1.
Abstract
BACKGROUND: The selection of an appropriate antimicrobial is a challenging task for clinicians. The Kirby-Bauer disk diffusion method is one of the most widely practiced antimicrobial susceptibility tests (AST). It is affected by many factors among which are the media used. Mueller-Hinton agar (MHA) is the standard medium recommended in guidelines. However, these guidelines are not strictly adhered to in some developing countries.Entities:
Keywords: CLSI; Disk diffusion method; Inhibition zones; Mueller-Hinton agar; Quality control
Mesh:
Substances:
Year: 2019 PMID: 30686832 PMCID: PMC6329728 DOI: 10.1186/s42506-018-0006-1
Source DB: PubMed Journal: J Egypt Public Health Assoc ISSN: 0013-2446
Clinical bacterial isolates
| Clinical bacterial isolates | Number |
|---|---|
|
| 50 |
|
| 49 |
|
| 17 |
|
| 20 |
|
| 3 |
|
| 10 |
Antibiotic susceptibility test results of reference bacterial strains on MH agar versus NA during 30 days of QC testing, Alexandria, 2015–2016
| Reference strains | Antibiotic tested | Out of range results/30 QC days* (compared to CLSI ranges) | |||
|---|---|---|---|---|---|
| MH | NA | ||||
| Larger IZs | Smaller IZs | Larger IZs | Smaller IZs | ||
| Ceftazidim (CAZ) | 0/30 | 0/30 | 13/30 | 2/30 | |
| Gentamicin (CN) | 0/30 | 0/30 | 4/30 | 13/30 | |
| Tobramycin (TOB) | 0/30 | 0/30 | 0/30 | 15/30 | |
| Piperacillin (PRL) | 1/30 | 2/30 | 6/30 | 9/30 | |
| Ciprofloxacin (CIP) | 2/30 | 0/30 | 19/30 | 2/30 | |
| Ampicillin (AMP) | 0/30 | 3/30 | 0/30 | 13/30 | |
| Cefazolin (KZ) | 0/30 | 1/30 | 0/30 | 13/30 | |
| Gentamicin (CN) | 0/30 | 2/30 | 0/30 | 6/30 | |
| Tobramycin (TOB) | 0/30 | 1/30 | 0/30 | 9/30 | |
| Tazobactam-piperacillin (TZP) | 0/30 | 0/30 | 2/30 | 6/30 | |
| Azithromycin (AZM) | 0/30 | 2/30 | 0/30 | 23/30 | |
| Clindamycin (DA) | 0/30 | 2/30 | 0/30 | 9/30 | |
| Cefoxitine (FOX) | 0/30 | 2/30 | 6/30 | 1/30 | |
| Penicillin (P) | 1/30 | 2/30 | 16/30 | 2/30 | |
| Sulfamethoxazol-trimethoprim (SXT) | 0/30 | 0/30 | 4/30 | 13/30 | |
*QC performed over 30 consecutive days
Antibiotic susceptibility test results of clinical bacterial isolates on MHA versus NA using CLSI zone size interpretative table HIPH, Alexandria, 2015–16
| Antibiotic/clinical isolate | SIR agreement* | Very major error | Major error | Minor error |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | |
| Ceftazidim (CAZ) | 46 (93.90) | 0 (0.00) | 3 (6.10) | 0 (0.00) |
| Gentamicin (CN) | 38 (77.55) | 8 (16.30) | 2 (4.10) | 1 (2.00) |
| Tobramycin (TOB) | 33 (67.30) | 10 (20.40) | 2 (4.10) | 4 (8.20) |
| Piperacillin (PRL) | 24 (49.00) | 0 (0.00) | 1 (2.00) | 24 (49.00) |
| Ciprofloxacin (CIP) | 36 (73.50) | 4 (8.20) | 2 (4.10) | 7 (14.30) |
| Total | 177 (72.24) | 22 (8.98) | 10 (4.08) | 36 (14.70) |
| Ampicillin (AMP) | 50 (100.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Cefazolin (KZ) | 46 (92.00) | 0 (0.00) | 1 (2.00) | 3 (6.00) |
| Gentamicin (CN) | 50 (100.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Tobramycin (TOB) | 47 (94.00) | 0 (0.00) | 0 (0.00) | 3 (6.00) |
| Tazobactam-piperacillin (TZP) | 48 (96.00) | 0 (0.00) | 0 (0.00) | 2 (4.00) |
| Total | 241 (96.40) | 0 (0.00) | 1 (0.40) | 8 (3.20) |
| Azithromycin (AZM) | 43 (86.00) | 0 (0.00) | 3 (6.00) | 4 (8.00) |
| Clindamycin (DA) | 41 (82.00) | 1 (2.00) | 0 (0.00) | 8 (16.00) |
| Cefoxitine (FOX) | 33 (66.00) | 10 (20.00) | 7 (14.00) | 0 (0.00) |
| Penicillin (P) | 44 (88.00) | 2 (4.00) | 4 (8.00) | 0 (0.00) |
| Sulfamethoxazol-trimethoprim (SXT) | 33 (66.00) | 6 (12.00) | 1 (2.00) | 10 (20.00) |
| Total | 194 (77.60) | 19 (7.60) | 15 (6.00) | 22 (8.80) |
*Category agreement with respect to susceptible (S), intermediate (I), and resistant (R) test results